Skip to content

A comparative clinical study to evaluate the effect of Nishadi Lauha Churna and Darvyadi Lauha Churna in patients with Iron Deficiency Anemia (Pandu Roga) in children

Efficacy of Nishadi Lauha Churna versus Darvyadi Lauha Churna in the management of Pandu Roga with special reference to Iron Deficiency Anemia An open labelled randomized comparative clinical trial - nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111717
Enrollment
40
Registered
2026-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D50- Iron deficiency anemia

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda, Jamnagar,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Mild and Moderate cases of Anemia according to WHO criteria and in peripheral blood smear- hypochromic, microcytic cell, Serum Iron less than 59 microgram per dL and TIBC more than 450 microgram per dL and children having cardinal sign of Pandu i.e. Panduta and any minimum two classical signs and symptoms of Pandu Roga/Iron deficiency Anemia. 2. Children on Oral medication for IDA (Those who are willing to get enrolled) will be included in the study after a washout period of two weeks.

Exclusion criteria

Exclusion criteria: 1. Children diagnosed with Haemoglobinopathies especially Thalassemia, Sickle cell anemia. 2. Children with condition Causing Chronic Blood loss like worm infestation, piles, anal polyps, hemophilia. 3. Children with congenital disorder and chronic debilitating diseases. 4. Children diagnosed with any other type of Anemia other than IDA 5. Anemia associated with any other systemic illness i.e. Malaria, Acute and Chronic Diarrhoea

Design outcomes

Primary

MeasureTime frame
Change in Laboratory investigation i.e. Hb%, Total Iron Binding Capacity (TIBC) and Serum Ferritin, Peripheral Blood SmearTimepoint: BT and AT within 12 weeks

Secondary

MeasureTime frame
To assess the improvement in Clinical Symptomatology of the patients (Panduta, Akshikootshotha, Aayasenshwasa, Hriddrava, Pindikodwestana, Daurbalya, Balakshaya and Aruchi) Scoring system will be adoptedTimepoint: BT and AT within 12 weeks

Countries

India

Contacts

Public ContactDr V K Kori

Institute of Teaching and Research in Ayurveda, Jamnagar,

drvkkori@yahoo.co.in9409207285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026